Chemotherapy and immunotherapy: mapping the road ahead.

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Cancer immunotherapy, particularly checkpoint blockade, is a standard treatment for many cancers.
• Cytotoxic chemotherapy has historically been used for direct tumor cell killing.
• Emerging evidence shows chemotherapy can modulate anti-cancer immune responses.

Purpose of the Study:

• To review recent advances in understanding chemotherapy's immunological effects.
• To discuss progress in combining chemotherapy with checkpoint blockade.
• To highlight challenges in translating preclinical findings to clinical practice.

Main Methods:

• Literature review of recent advances in cancer immunotherapy and chemotherapy.
• Analysis of mechanisms by which chemotherapy affects the immune system.
• Discussion of clinical trial progress and challenges.

Main Results:

• Chemotherapy can enhance anti-cancer immunity through mechanisms like immunogenic cell death, improved antigen presentation, and depletion of immunosuppressive cells.
• Combining chemotherapy with checkpoint blockade shows promise in preclinical studies.
• Translating these combinations into effective clinical treatments faces significant hurdles.

Conclusions:

• Chemotherapy is a potent modulator of the anti-cancer immune response, offering synergistic potential with checkpoint inhibitors.
• Further research is needed to overcome challenges in combining chemotherapy and immunotherapy for improved patient outcomes.